Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Efficacy and cardiovascular safety appear similar per the PATCH trial updated at ESMO 2024. How would you counsel patients who decline LHRH agonists?
Answer from: Medical Oncologist at Academic Institution
My default form of ADT remains a GnRH agonist or antagonist but estradiol transdermal patches are clearly effective and safe as an alternative option for men who either 1) have significant loss of bone density/osteoporosis, 2) have significant hot flashes with traditional ADT and wish to try an alte...